TGTX Q2 2018 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000-0.2% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$44M-116697.4% margin

Net Income

-$44M-116163.2% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$141M

Total Liabilities

$141M

Stockholders' Equity

$101M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,095	-0.2%
Gross Profit	$38,000	$38,095	-0.2%
Operating Income	-$44M	-$28M	-56.0%
Net Income	-$44M	-$28M	-55.7%